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EPIDEMIOLOGY
HIV-Associated Anemia After 96 Weeks on Therapy:
Determinants Across Age Ranges in Uganda and Zimbabwe
Devan Jaganath,1 A. Sarah Walker,2 Francis Ssali,3 Victor Musiime,3 Francis Kiweewa,3 Cissy Kityo,3
Robert Salata,4 and Peter Mugyenyi,3 for the DART and ARROW Trials
Abstract
Given the detrimental effects of HIV-associated anemia on morbidity, we determined factors associated with
anemia after 96 weeks of antiretroviral therapy (ART) across age groups. An HIV-positive cohort (n = 3,580) of
children age 5–14, reproductive age adults 18–49, and older adults ‡ 50 from two randomized trials in Uganda
and Zimbabwe were evaluated from initiation of therapy through 96 weeks. We conducted logistic and mul-
tinomial regression to evaluate common and differential determinants for anemia at 96 weeks on therapy. Prior
to initiation of ART, the prevalence of anemia (age 5–11 < 10.5 g/dl, 12–14 < 11 g/dl, adult females < 11 g/dl,
adult males < 12 g/dl) was 43%, which decreased to 13% at week 96 ( p < 0.001). Older adults had a signifi-
cantly higher likelihood of anemia compared to reproductive age adults (OR 2.60, 95% CI 1.44–4.70,
p = 0.002). Reproductive age females had a significantly higher odds of anemia compared to men at week 96
(OR 2.56, 95% CI 1.92–3.40, p< 0.001), and particularly a greater odds for microcytic anemia compared to
males in the same age group ( p= 0.001). Other common factors associated with anemia included low body mass
index (BMI) and microcytosis; greater increases in CD4 count to week 96 were protective. Thus, while ART
significantly reduced the prevalence of anemia at 96 weeks, 13% of the population continued to be anemic.
Specific groups, such as reproductive age females and older adults, have a greater odds of anemia and may
guide clinicians to pursue further evaluation and management.
Introduction
Anemia is estimated to affect 1.62 billion people, oralmost a quarter of the world’s population.1 It is a
common complication of HIV infection, with etiologies in-
cluding HIV infection itself, gastrointestinal and menstrual
blood loss, opportunistic infections, neoplasms, medications,
and malnutrition.2–4 In sub-Saharan Africa, conditions in-
cluding malaria, hookworm, tuberculosis, and hemoglobin-
opathies also contribute to anemia.2 HIV-associated anemia
has considerable consequences, including a worse quality of
life and increased mortality, independent of markers such as
CD4 or viral load.2,5–7
Antiretroviral therapy (ART) reduces the prevalence of
HIV-related anemia.8–11 However, studies suggest over 30%
prevalence of anemia even while on ART, and it continues to
predict mortality and poor quality of life.2,4,8–10,12 The
studies have been largely from developed countries and have
focused on early determinants of anemia, primarily among
individuals of reproductive age. With greater access to ART
in sub-Saharan Africa, the HIV population has a wider age
range and has been on therapy for several years. As HIV-
infected individuals transition through life stages, it is im-
portant to understand the similarities and differences of risk
factors for anemia. Utilizing two large pediatric and adult
trials in Uganda and Zimbabwe, we investigated the preva-
lence and risk factors for HIV-related anemia after 96 weeks
on ART, among children 5–14, reproductive age adults, and
older adults greater than 50 years old.
Materials and Methods
Anemia was evaluated among participants in the Delivery
of Antiretroviral Therapy in Africa (DART) (ISRCTN
13968779) and Antiretroviral Research for Watoto (ARROW)
(ISRCTN 24791884) trials in three sites in Uganda and one in
Zimbabwe.13,14 The primary aim of these trials was a ran-
domized comparison of clinically driven monitoring (CDM)
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to laboratory with clinical monitoring (LCM) of ART. The
primary efficacy outcome was new nonrecurrent WHO
stage 4 clinical events and/or death; the primary toxicity
outcome was serious adverse events (SAEs) in DART
and Grade 3/4 AEs in ARROW. Neither trial found sig-
nificant differences in toxicity outcomes between CDM
and LCM,13,14 so data from both randomized groups were
pooled for this analysis.
We sought to investigate anemia after 96 weeks on ther-
apy, and therefore included DART and ARROW participants
who were alive and in follow-up 96 weeks after ART initi-
ation. Participants were ART naive prior to enrollment,
except for past exposure to prevent mother-to-child trans-
mission (PMTCT) of HIV. For the DART study, adults (18
years or older) were eligible if they had a CD4 count < 200
cells/mm3 and WHO stage 2 or greater. For the ARROW
study, children 5–14 were eligible if they met WHO 2006
pediatric guidelines for ART (CD4 < 200 cells/mm3 and/or
WHO stage 3 or 4 disease).15 Younger children face unique
factors for anemia including early childhood infections,
PMTCT exposure, and birth complications that we were
unable to compare across groups, and thus were excluded
from the analysis. Exclusion criteria in both trials included
signs of an acute infection, contraindications to take ART due
to concomitant medications or abnormal laboratory values, or
pregnancy/breastfeeding in women.
After enrollment, participants were initiated on ART. In
2003–2004, DART participants received zidovudine/lami-
vudine plus tenofovir, abacavir, or nevirapine, with 600
participants randomized to abacavir vs. nevirapine.16 From
2007–2008, ARROW participants received one of two regi-
mens: abacavir/lamivudine plus a nonnucleoside reverse
transcriptase inhibitor (NNRTI, nevirapine or efavirenz) or a
four-drug regimen of abacavir/lamivudine, zidovudine, and
an NNRTI. After 36 weeks, ART regimens of those in the
four-drug regimen were reduced to three drugs, removing
either zidovudine or the NNRTI, as per the ARROW trial
protocol.14
Follow-up included symptom assessment every 4–6 weeks
and clinical examination and lymphocytic (CD4/CD8) and
hematological testing every 12 weeks. Whereas results from
LCM participants were given to clinicians, results for CDM
participants were given upon request to inform clinical
management (except for CD4 count, which was never re-
turned) or if there was grade 4 toxicity that had not already
been requested (protocol safety criteria).13,14
Anemia in this analysis was defined according to WHO
guidelines, adjusted for African ethnicity.17 For adults 15
years of age or older, anemia was defined as hemoglobin
< 12.0 g/dl in males and < 11.0 g/dl in females. Children 5–11
years were considered anemic if they had a hemoglobin
< 10.5 g/dl, and for children 12–14 years, anemia was a he-
moglobin < 11.0 g/dl. Mild anemia was defined as 10.0–
11.9 g/dl in male and 10.0–10.9 g/dl in female adults 15 years
and older, 10–10.4 g/dl in children 5–11 years, and 10–10.9 g/
dl in children 12–14 years. Moderate anemia was defined as
7.0–9.9 g/dl, and severe anemia was less than 7.0 g/dl, in all
ages. Microcytosis in adults was defined as a mean corpus-
cular volume (MCV) less than 80 fl and macrocytosis if
greater than 100 fl. For children ages 5–11 years, the normal
MCV range was 70–92 fl, and for children 12–14 the MCV
normal range was 76–102 fl. Microcytic, normocytic, or
macrocytic anemia was defined as anemia with microcytosis,
normocytosis, or macrocytosis, respectively. To assess nu-
tritional status, low body mass index (BMI) was defined as a
BMI < 18.5 kg/m2 for adults, whereas for children, it was
defined as a BMI-for-age Z score (UK) of £ 2.
The cohort was stratified into three age groups for analysis:
children ages 5–14 years, reproductive age adults 18–49
years, and older adults greater than 50 years. Wilcoxon
signed-rank test and McNemar’s test were used to compare
pre-ART and week 96 variables. Therefore, by definition,
analysis included those with follow-up at 96 weeks [639 of
667 (96%) in ARROW age < 14, and 3,006 of 3,316 (91%) in
DART]. Of these individuals, hemoglobin measurements
were available for 635 (99%) in ARROW and 2,945 (98%) in
DART. Simple and multiple logistic regression and multi-
nomial logistic regression were used to identify risk factors
for anemia at week 96 from pre-ART and week 96 variables.
Variables were included in the multiple logistic models if the
p-value was < 0.20 on univariate testing. Heterogeneity of
risk factors between age groups was evaluated by assessing
the significance ( p < 0.05) of the interaction term between
age group and the given risk factor. Hosmer–Lemeshow
goodness of fit testing with 10 quantiles was used to evaluate
the final model.
The DART and ARROW studies received ethical approval
from their respective institutions in Uganda, Zimbabwe, and
the United Kingdom. This substudy analysis was also re-
viewed and approved by the Institutional Review Board of
the Joint Clinical Research Centre ( JCRC) and the Uganda
National Council for Science and Technology (UNCST).
Results
A total of 3,580 HIV-infected children and adults were
included in the analysis, of whom 635 (18%) were children
aged 5–14 years, 2,750 (77%) adults aged 18–49 years, and
195 (5%) adults older than 50 years. Characteristics at initi-
ation of ART and week 96 are summarized in Table 1. CD4
count improved significantly in all age groups, from an
overall median of 98 cells/mm3 pre-ART to 271 cells/mm3 at
week 96 ( p < 0.001), as did nutritional status with an overall
reduction in those subjects with low BMI from 17% to 5%
( p < 0.001). Prior to initiation of ART, 1,527 individuals
(43%) had anemia, including 217 (34%) children, 1,228
(45%) reproductive age adults, and 82 (42%) older adults.
Among those with anemia, 451 (30%) had microcytic ane-
mia, 1,009 (66%) had normocytic anemia, and 67 (4%) had
macrocytic anemia. At 96 weeks, there was a significant re-
duction in the prevalence of anemia to 482 cases (13%), in-
cluding 44 children (7%), 407 (15%) reproductive age adults,
and 31 (16%) older adults ( p < 0.001 for all groups and
overall).
Among those with anemia at 96 weeks, 56 cases (12%)
were microcytic, 250 (52%) were normocytic, and 174 (36%)
were macrocytic. Severe anemia ( < 7 g/dl) was rare, with 2
cases pre-ART initiation and 11 cases at week 96 (< 1%).
Iron use was minimal in this cohort, with 24 individuals
( < 1%) taking iron supplements between weeks 94 and 98.
Similarly, there were limited cases of malaria [clinical or
blood slide confirmed, n = 28 (1%)], acute febrile illness
(n = 2, < 1%), or WHO stage 3/4 events (n = 14, < 1%) be-
tween weeks 94 and 98. WHO 3/4 events included HIV
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wasting, cryptococcosis, cryptosporidiosis, esophageal can-
didiasis, and extrapulmonary TB.
Univariate testing was conducted to suggest possible risk
factors for anemia after 96 weeks on therapy (Supplementary
Table S1; Supplementary Data are available online at
www.liebertpub.com/aid). Prior to initiation of ART, female
gender, a low BMI, anemia at initiation, and microcytosis
were associated with anemia, while higher CD4 counts pro-
tected against the development of anemia (Supplementary
Table S1). Characteristics at week 96 associated with anemia
included low BMI, microcytosis, zidovudine use, pregnancy,
and having a WHO stage 3/4 event. Cotrimoxazole use and
higher pre-ART CD4 were associated with lower odds of
anemia.
In the multiple logistic model (Tables 2 and 3), older adults
had greater than twice the odds of anemia compared to re-
productive age individuals (OR 2.63, 95% CI 1.45–4.78,
p = 0.001). There was significant heterogeneity of the impact
of gender (p < 0.001), with females in the reproductive age
group having an increased likelihood of anemia (OR versus
males 2.56, 95% CI 1.92–3.40, p< 0.001), whereas odds were
similar in males and females in the other groups. While low
BMI at initiation of ART was not a significant risk factor,
individuals with a low BMI at week 96 had over three times
the likelihood of anemia (OR 3.47, 95% CI 2.25–5.34,
p < 0.001). There appeared to be increased odds in adults
compared to children, but heterogeneity was not statistically
significant ( p = 0.42). Greater CD4 increases from pre-ART
baseline were associated with reduced likelihood of anemia
(OR 0.87 per every 100 cells/mm3 increase from week 0 to
96, 95% CI 0.81–0.94, p < 0.001), and the effect was greatest
among reproductive age adults (heterogeneity p = 0.002).
Zidovudine use did not have a significant effect overall, but
odds of anemia appeared to be marginally increased among
Table 2. Multiple Logistic Regression
for Risk Factors of Anemia at Week 96
OR 95% CI p-value
Age group
Child 1.91 1.01, 3.62 0.05
Reproductive age 1.00
Older adult 2.60 1.44, 4.70 0.002
Female
Female and child 0.89 0.46, 1.70 0.72
Female and reproductive age 2.40 1.82, 3.18 < 0.001
Female and older age 0.66 0.29, 1.53 0.34
Prior to initiation of ART
Low baseline BMI 0.96 0.71, 1.29 0.78
CD4 (cells/mm3)
350 + 0.50 0.22, 1.16 0.11
200–349 0.79 0.36, 1.71 0.54
100–199 1.00
0–99 0.81 0.65, 1.01 0.06
Anemia pre-ART 3.30 2.65, 4.11 < 0.001
Microcytosis 1.51 1.18, 1.92 0.001
Week 96
Low BMI 3.47 2.25, 5.34 < 0.001
CD4 Change
(per 100 cells/mm3)
from baseline
0.87 0.81, 0.94 < 0.001
Microcytosis 2.76 1.84, 4.15 < 0.001
Zidovudine usea 1.10 0.81, 150 0.52
Cotrimoxazole Usea 0.91 0.73, 1.14 0.42
WHO stage 3/4 eventa 1.80 0.50, 6.51 0.37
aDefined if taken or occurred between weeks 94 and 98.
Hosmer–Lemeshow goodness of fit p = 0.27.
Table 3. Multiple Logistic Regression by Age Group for Risk Factors of Anemia at Week 96
Children Reproductive age Older adults
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value p valuea
Female 0.81 0.42, 1.54 0.51 2.56 1.92, 3.40 < 0.001 0.74 0.30, 1.79 0.50 < 0.001
Prior to initiation of ART
Low baseline BMI 0.61 0.22, 1.70 0.35 1.03 0.74, 1.43 0.85 0.94 0.26, 3.40 0.93 0.47
CD4 (cells/mm3) 0.89
350 + 0.55 0.20, 1.50 0.24
200–349 0.81 0.31, 2.11 0.67
100–199 1.00 1.00 1.00
0–99 1.07 0.41, 2.77 0.90 0.80 0.63, 1.02 0.07 1.03 0.43, 2.45 0.95
Anemia pre-ART 1.57 0.81, 3.06 0.18 3.64 2.85, 4.64 < 0.001 3.68 1.46, 9.29 0.01 0.13
Microcytosis 2.29 0.94, 5.57 0.07 1.47 1.13, 1.90 0.004 1.41 0.44, 4.56 0.56 0.55
Week 96
Low BMI 1.15 0.13, 10.6 0.90 3.39 2.14, 5.36 < 0.001 5.84 0.95, 36.08 0.06 0.42
CD4 change
(per 100 cells/mm3)
from baseline
0.95 0.90, 1.00 0.05 0.76 0.68, 0.84 < 0.001 0.94 0.64, 1.37 0.73 0.002
Microcytosis 4.04 0.79, 20.53 0.09 2.77 1.79, 4.28 < 0.001 1.40 0.18, 11.06 0.75 0.54
Zidovudine useb 1.91 1.00–3.63 0.05 0.87 0.62, 1.23 0.43 3.34 0.62, 18.24 0.16 0.06
Cotrimoxazole Useb 0.95 0.28, 3.28 0.94 0.90 0.71, 1.14 0.39 0.63 0.26, 1.53 0.31 0.88
aHeterogeneity p-value evaluating the interaction between the risk factor and age group.
bDefined if taken or occurred between weeks 94 and 98.
Hosmer–Lemeshow goodness of fit (children p = 0.60, reproductive p = 0.20, older p = 0.62).
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children ( p = 0.05). There was no effect of cotrimoxazole on
anemia overall or in any subgroup ( p = 0.42).
Given the interaction between gender and age group, we
explored the impact of age and gender on subtypes of anemia
at week 96 (Table 4). Multinomial logistic regression found
that compared to males in the same age strata, reproductive
age females had significantly higher odds of microcytic
anemia (OR 33.27, 95% CI 4.54–243.72, p = 0.001), adjusted
for low BMI and CD4. They also had a significantly greater
odds of both normocytic ( p < 0.001) and macrocytic
( p = 0.003) anemia compared to reproductive age males.
There were no other significant differences between males
and females on subtype of anemia among children or older
adults. In a separate multivariable logistic regression analysis
among women of reproductive age, we also found that cur-
rent pregnancy was associated with a significant 2.5 times
greater odds of anemia at week 96 (data not shown).
Discussion
HIV-associated anemia is a multifactorial disease that
continues to complicate care despite greater access to ther-
apy. By exploring the burden and risk factors for HIV-
associated anemia after 96 weeks on therapy, we evaluated
the similarities and differences across different life stages to
illuminate potential relationships that can guide evaluation
and management of HIV-positive patients in resource-limited
settings similar to Uganda and Zimbabwe.
Prior to starting therapy, there was a high prevalence of
anemia at 43%. This is consistent with other studies in sub-
Saharan Africa that demonstrate a pre-ART prevalence of
anemia of 63–77.4%.8,11 This reflects low-grade anemia,
with only two cases of severe anemia at initiation. After 96
weeks on ART, the prevalence significantly decreased to
13%, and all age groups had increases in hemoglobin. This is
similar to HIV-negative individuals in related settings; a
study in Rwanda found that HIV-negative women had an
anemia prevalence of 8%.18 Given there are an estimated
767,292 individuals currently on therapy in Uganda and
Zimbabwe, 13% still represents almost 100,000 individuals
and a continued burden among this population.19
In evaluating the possible factors associated with anemia,
there were few acute clinical events that occurred around
week 96, including malaria, WHO stage 3 or 4 events, or
acute febrile illness. Older individuals had over twice the
odds of anemia compared to reproductive age individuals,
adjusted for extent of HIV infection, nutritional status, and
therapy. In sub-Saharan Africa, there are an estimated 3 mil-
lion individuals greater than 50 years old living with HIV/
AIDS.20 HIV infection and/or the effects of therapy may ac-
celerate the onset of comorbidities associated with aging.21
Regardless of HIV infection, older individuals also have an
increased risk of anemia, as a consequence of other co-
morbidities, increased inflammation, and reduced erythropoi-
etic function.22 In our sample, older adults represented only
5% of the sample, and thus definitive conclusions are limited.
However, with a rising number of HIV-infected individuals
entering into older ages, it is important to understand that they
face a greater likelihood of anemia while on therapy that may
guide further management by practitioners.
HIV infection can promote malnutrition via opportunistic
infections and chronic inflammation, while malnutrition can
dysregulate immune function.23 We found that independent
of HIV disease extent, low BMI was associated with over
three times the odds of anemia at week 96, especially among
adults. While there was no significant effect within the pe-
diatric subgroup, the power to detect effects within the dif-
ferent subgroups was limited. Moreover, microcytosis prior
to ART initiation and at week 96 was associated with anemia
among children, and may reflect a more child-specific
mechanism of malnutrition through iron deficiency. Several
studies show a high burden of iron deficiency anemia in HIV-
infected children, with benefits after supplementation.24–26
The association of hemoglobin, CD4, and progression of
HIV infection is well established.10,11,27,28 Consistent with
these findings, we found lower odds of anemia in those with
higher increases in CD4 counts from pre-ART baseline. Sur-
prisingly, we found that those with pre-ART CD4 less than 100
cells/mm3 also had a marginal level of protection. This could
be due to a survival bias; those who had a low CD4 count and
survived to 96 weeks may have had a good response to ART,
whereas those with low CD4 count who died in the first 96
weeks were not included in our analysis by design. This is
supported by another substudy from the DART and ARROW
trials, which found mortality rates of 3.3% of children and
5.4% of adults in the first year after initiation of therapy, and
demonstrated that low hemoglobin levels were an independent
predictor of mortality early after initiation of therapy.29 He-
moglobin has been suggested as a marker of virological fail-
ure,30,31 and thus patients with anemia may need to be closely
evaluated for signs of treatment failure.
While zidovudine-based regimens are associated with an
overall increase in hemoglobin levels,28,32 macrocytic ane-
mia is a well-known complication.8,33 This is reflected in the
large increase in prevalence of macrocytosis, from 4% to
49% overall. Although we did not find an overall effect of
zidovudine use, children on zidovudine had a marginally
increased association with anemia. However, it is important
Table 4. Multinomial Logistic Regression on the Effects of Gender and Age on Anemia Subtype
Microcytic anemia (56 cases) Normocytic anemia (250 cases) Macrocytic anemia (174 cases)
ORa 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Child female vs. male 0.44 0.04, 4.96 0.51 0.85 0.41, 1.77 0.67 0.57 0.13, 2.42 0.45
Reproductive age
female vs. male
33.27 4.54, 243.72 0.001 3.25 2.22, 4.77 < 0.001 1.79 1.22, 2.64 0.003
Older female vs. maleb 0.76 0.18, 3.10 0.70 0.51 0.17, 1.48 0.22
aAdjusted for CD4 category and low BMI at week 96.
bOnly two older women (0 men) had microcytic anemia at week 96.
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to note that children did not have episodes of severe ane-
mia,14 and therefore any impact of zidovudine is restricted to
low-grade anemia. In addition, recent WHO treatment
guidelines do not recommend zidovudine in first line therapy
for adults, and thus future studies may demonstrate a further
reduction in anemia at 96 weeks of therapy with newer
regimens.34
In comparing the association of anemia across age groups,
we found a large and specific effect among women of re-
productive age. Several cohorts have found HIV-infected
women have a greater risk of anemia compared to both HIV-
negative women and HIV-positive men, and anemia is an
independent predictor of mortality.7,10,35–38 The cause of this
increased risk is likely due to menstruation and pregnancy,
associated with blood loss and greater micronutrient re-
quirements including iron.39–41 Consistent with this, we
found that reproductive age women, but not females in the
other age groups, had a significantly increased association
of microcytic anemia compared to males. Women also had
increased odds of normocytic anemia, which may reflect
blood loss or a combination effect of microcytic and mac-
rocytic anemia from zidovudine and/or cotrimoxazole use.
Increased odds of macrocytic anemia in this age range may
be due to differences in adherence,42 but warrants further
investigation. As HIV-infected girls enter into adulthood,
they enter a specific period where they have a significantly
greater likelihood of anemia and may benefit from micro-
nutrient supplementation.43 At the same time, there is evi-
dence that HIV-infected women enter menopause at an
earlier age,44 when these effects would be reduced and other
factors of older age may take precedence as a basis for
anemia.
There are several advantages to our study in contributing to
our understanding of HIV-associated anemia. Studies on this
topic have been conducted largely in developed countries, or
have been in adults or pregnant women. In our analysis, we
have included a large sample from sub-Saharan Africa, en-
compassing a wide age range to allow for stratification and
comparison of groups. The period of 96 weeks was chosen
primarily because past studies have focused on the first year
on therapy. However, several studies have shown that there
may be initial effects from therapy or continued effects from
HIV infection.5,8,29 We sought to describe factors associated
with anemia at a later time point to reflect a population in a
resource-limited setting that had survived and had been on
therapy for a prolonged period.
At the same time, there were limitations to our analysis that
suggest areas for further exploration. We would have bene-
fited from greater etiological testing, including red blood cell
indices, iron studies, assessment for helminthic infection
diagnosis, and evaluation of hemoglobinopathies. We also
did not have HIV-negative cases that would have allowed us
to compare the 13% prevalence of anemia to the background
population. While the cohort we created deliberately in-
cluded those who were alive at week 96, this excluded those
who died prior to this period; results are therefore general-
izable primarily to a population that responds to ART and
does not experience early mortality.
The cohort included individuals who had advanced dis-
ease; although recent guidelines have expanded to those
with CD4 £ 500 cell/mm3,34 experience in high-income
countries suggests that late presenters will continue to
contribute a large minority.45 Though severe anemia may
have been a more specific outcome, this represented only a
small percentage of our sample and power was too low to
attempt this. While we benefited from data from two large
randomized trials conducted by similar trials groups, there
are limitations in pooled analysis, including differences in
the period of evaluation, staff, and therapy given between
the two studies. However, both trials recruited adults and
children from identical centers in Uganda and Zimbabwe, so
underlying populations should have been similar. While
there may be differences between geographic sites, inclu-
sion criteria and overall care were standardized among all
centers.
While ART improves anemia status in HIV-infected in-
dividuals in resource-limited settings, there are other factors
that contribute to anemia across age groups. As HIV-infected
individuals age, greater investigation of anemia status may be
required during specific periods, including reproductive age
females and adults as they enter older age.
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